"Product Profiles: Inflammatory Bowel Disease - Products Compete for Underserved Patient Groups" Published
Datamonitor foresees rising competition in the Crohn's disease and ulcerative colitis markets over the next five years. Several pipeline and marketed drugs are competing to garner patient share from dominant brand Remicade (infliximab; Janssen Biotech/Merck & Co./Mitsubishi Tanabe). High unmet need for an efficacious maintenance therapy appears to be a key driver for these products.
View full press release